The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemoradiotherapy for potentially resectable esophageal squamous cell carcinoma and the significance of Rad51 expression as a factor predictive of the treatment response.
Hiroshi Saeki
No relevant relationships to disclose
Tomonori Nakanoko
No relevant relationships to disclose
Hajime Ohtsu
No relevant relationships to disclose
Hiroyuki Kawano
No relevant relationships to disclose
Koji Ando
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Takefumi Ohga
No relevant relationships to disclose
Masaru Morita
No relevant relationships to disclose
Yoshihiro Kakeji
No relevant relationships to disclose
Yasushi Toh
No relevant relationships to disclose
Yoshihiko Maehara
No relevant relationships to disclose